<DOC>
	<DOCNO>NCT02376036</DOCNO>
	<brief_summary>The primary goal Phase 1 study ass safety tolerability one MGD010 intravenous ( IV ) infusion healthy adult volunteer .</brief_summary>
	<brief_title>Phase 1 Study MGD010 Healthy Subjects</brief_title>
	<detailed_description>This Phase 1 study evaluate safety , tolerability PK MGD010 , CD32B x CD79B DART bi-specific antibody-based molecule . This study conduct double-blind , randomize , placebo control , single ascend dose study among healthy subject .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Between 18 50 year age Body mass index ( BMI ) 18 30 kg/m2 , inclusive Women childbearing potential ; Women pregnant breastfeed Any significant acute chronic medical illness Any major surgery within 4 week study drug administration Active latent tuberculosis ( TB ) Active latent Hepatitis B , Hepatitis C HIV infection History allergy monoclonal antibody , significant drug allergy ( anaphylaxis ) , hypersensitivity component test reference investigational product formulation . Evidence organ dysfunction clinically significant deviation normal Vaccination live vaccine , use prescription drug , within 4 week study drug administration Known history infection exposure Hepatitis A virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Normal healthy volunteer</keyword>
</DOC>